We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : MLSC Blood decontaminant recieves patent!!!

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cindy Powell who wrote (193)3/31/2001 12:11:54 AM
From: Cindy Powell  Read Replies (1) of 196
Ninth MDI Patent Expands Security of Basic Technology

SALT LAKE CITY, March 28 /PRNewswire/ -- Medical Discoveries, Inc. (OTC: MLSC - news) has been notified that Japanese Patent Application Number 508856/96 entitled ``System And Method For Carrying Out Sterilization'' will issue in the near future.

The new patent claims priority to U.S. Patent No. 5,507,932, ``Apparatus For Electrolyzing Fluids,'' issued to Medical Discoveries, Inc. in 1996. This patent was the second in a family of additional patents in the U.S. and elsewhere that defines and safeguards the proprietary electrolysis technology used by MDI.

Once this patent issues, Medical Discoveries, Inc. (MDI) will have a total of nine granted patents relating to the company's proprietary electrolysis devices, methods, and the patented products and application derived therein. The family of patents represents the continued development of MDI's technology and intellectual property, which began in 1992 with proprietary hydrolysis of saline solution for microbicidal applications and the development of a patented machine to produce these products.

Newly allowed Japanese Patent Application Number 508856/96, once issued, will cover similar subject matter in Japan as that claimed in U. S. Patent 5,507,932. Specifically, an apparatus for electrolyzing fluids for in vivo treatment of physiological fluids for the destruction of microbes in warm-blooded animals is claimed. The apparatus can be used with a variety of fluids including whole blood, plasma and cell-containing fluids, without introducing harmful substances into the electrolyzed fluids.

MDI's patents and resulting intellectual properties now span more than a decade of research and development. Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi. In 1994, the Company received its first patent relating to a drug based upon its proprietary electrolysis technology. This drug bears the code name MDI-P.

Formed in 1991, Medical Discoveries, Inc. is a public traded (OTC: MLSC - news) development-stage biopharmaceutical research company (as defined in SFAS No. 7) engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications.

Information in this press release relating to the potential of MDI and MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statement because of a number of risks and uncertainties, including but not limited to MDI's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.

SOURCE: Medical Discoveries, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext